Sahajanand Medical Technologies IPO

About Sahajanand Medical Technologies Company

Sahajanand Medical Technologies, formed as a partnership in 1999 and incorporated in October 2001, has evolved from an Indian coronary-stent manufacturer into a research-driven medical-device company focused on vascular intervention and structural-heart therapy. Its core portfolio includes drug-eluting coronary stents and PTCA balloons under the Supraflex and Sironity brands, drug-coated balloons, transcatheter aortic valve implantation systems under Hydra, and occluders under Cocoon, along with renal stents and peripheral vascular devices. The company’s expertise spans device design, biodegradable-polymer drug-release technology, balloon and stent engineering, precision manufacturing, clinical studies, regulatory compliance and global commercialisation; it operates manufacturing facilities in Surat and Hyderabad, India, and Nonthaburi, Thailand, supported by R&D centres in India and Thailand. Its distinctive strengths include being the first company worldwide to receive CE certification for a drug-eluting stent using a biodegradable polymer, developing ultra-thin-strut stent technology, and building clinical evidence through more than 75 completed and ongoing studies. Important customers are interventional cardiologists, hospitals and hospital chains, including Narayana Hrudayalaya, as well as distributors, regulators and healthcare providers across 77 countries, served through direct, hybrid and distributor-led channels. Sahajanand engages clinicians and institutions through clinical evidence, training, technical support, regulatory-aligned product supply and market-specific distribution, seeking to improve access to advanced cardiovascular care while addressing clinical complexity, affordability, procedural outcomes and evolving global regulatory requirements.